Nitin Jain, Professor of Medicine at The University of Texas MD Anderson Cancer Center, shared on X:
”Very pleased to announce that our Investigator initiated trial of BGB-16673 (Tacabrutideg) + sonrotoclax for patients with treatment naive CLL is now open for enrollment.
Tacabrutideg = BTK degrader
Sonrotoclax = BCL2 inhibitor
This study is in part supported by ASCO YIA grant to Hannah Goulart.
A big thanks to BeOne team for close collaboration with this study.
You can email/DM me for details.”
You can also read: CLL-TIM Predicts Infection Risk and Treatment Need in Newly Diagnosed CLL – ecancer
